Sprycel Receives Approval in Canada

The CML Society of Canada is delighted to learn that there is a new product on the market, Sprycel, that is indicated for adult patients in whom current treatment has failed or have developed intolerance. This brings renewed hope and a sense of a new lease on life.

We are very encouraged by the continuing research in the area of CML.

Congratulations to Bristol-Myers Squibb for receiving such quick approval for this important new drug.

Video Clip Click on the link to view the video news clip